Mind Medicine (MindMed) Inc. (MNMD)'s MM120 Earns FDA Breakthrough Status in Anxiety Treatment

We recently compiled a list of the 13 Best Psychedelic Stocks to Invest in Now. Mind Medicine (MindMed) Inc. stands fourth among them.

Mind Medicine (MindMed) Inc. (NASDAQ:MNMD), a clinical-stage biopharmaceutical company, is developing innovative treatments for brain health disorders, focusing on generalized anxiety disorder (GAD) and major depressive disorder (MDD). Its lead candidate, MM120 ODT (Lysergide D-tartrate), has received FDA Breakthrough Therapy Designation and is progressing through three pivotal Phase 3 trials, while MM402 (R(-)-MDMA) is in Phase 1 trials for Autism Spectrum Disorder.

Recent corporate updates in August 2025 highlighted significant clinical momentum. The Voyage study for GAD is expected to report results in the first half of 2026, with Panorama (GAD) and Emerge (MDD) topline data anticipated in the second half of 2026. These trials aim to offer fast-acting, durable treatment options for large, underserved patient populations, potentially transforming psychiatric care.

Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) maintains a strong financial position, with $238 million in cash and investments as of June 2025, supporting operations into 2027 and ensuring sustained progress across its Phase 3 programs. This stability allows the corporation to advance high-priority psychiatric therapies without immediate funding pressures.

The business’s strategic focus on high-burden disorders addresses outdated treatment paradigms, as many patients fail first-line therapies, and the last FDA approval for GAD was in 2007. MM120 ODT’s potential for rapid, intermittent dosing positions it as a transformative therapy for GAD and MDD.

Additionally, new employee inducement grants demonstrate efforts to retain talent critical for advancing the Mind Medicine (MindMed) Inc. (NASDAQ:MNMD)’s ambitious development agenda.

While we acknowledge the potential of MNMD as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure. None.